Skip to main content
SpringerLink
Log in

Controlling BCG Vaccine’s Cell Viability in the Process of Its Production by an Bioluminescent ATP Assay

  • Published:
Moscow University Chemistry Bulletin Aims and scope

Abstract

The Bacille Calmette–Guerine (BCG) vaccine, which is based on a live strain of Mycobacterium bovis BCG is widely used for the immunoprophylaxis of tuberculosis. One of the BCG vaccine’s key parameters is its сell viability (specific activity: the number of colony forming units, CFUs), which is traditionally defined by the microbiological method. In this work, the rapid and selective bioluminescent method of intracellular ATP assay is used to control the BCG vaccine’s viability at various stages of the vaccine’s production. It permits us to reduce the time required for the analysis from 28 days to 1 h. The correlation is shown between the viability of a liquid BCG vaccine measured by the microbiological method compared to one calculated using the content of intracellular ATP, as well as the correlation between the CFU value for the lyophilized BCG vaccine and the ATP content in the liquid vaccine before lyophilization.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.

Similar content being viewed by others

REFERENCES

  1. Ho, M.M., Corbel, M.J., Knezevic, I., and Roumian-tzeff, M., Vaccine, 2005, vol. 23, no. 50, p. 5700.

    Article  Google Scholar 

  2. Lundin, A., Methods Enzymol., 2000, vol. 305, p. 346.

    Article  CAS  PubMed  Google Scholar 

  3. Lomakina, G.Yu., Modestova, Yu.A., and Ugarova, N.N., Biochemistry (Moscow), 2015, vol. 80, no. 6, p. 701.

    Article  CAS  Google Scholar 

  4. Stefanova, T., Biotechnol. Biotechnol. Equip., 2014, vol. 28, no. 3, p. 387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Jensen, S.E., Hubrechts, P., Klein, B.M., and Haslow, K.R., Biologicals, 2008, vol. 36, no. 5, p. 308.

    Article  CAS  PubMed  Google Scholar 

  6. Ho, M.M., Markey, K., Rigsby, P., Jensen, S.E., Gairola, S., Seki, M., Castello-Branco, L.R., Lopez-Vidal, Y., Knezevic, I., and Corbel, M.J., Vaccine, 2008, vol. 26, no. 36, p. 4754.

    Article  CAS  PubMed  Google Scholar 

  7. Kolibab, K., Derrick, S.C., Jacobs, W.R., and Morris, S.L., J. Microbiol. Methods, 2012, vol. 90, no. 3, p. 245.

    Article  CAS  PubMed  Google Scholar 

  8. Soni, G.R., Guidance Document on Quality Control of Bacillus Calmette-Guerin (BCG) Vaccine, Noida: Natl. Inst. Biologicals of India, 2014, p. 3

    Google Scholar 

  9. Singh Jadaun, G.P., Kasana, H., and Malik, N., Int. J. Vaccine Res., 2016, vol. 1, no. 1, p. 4.

    Google Scholar 

  10. Jin, T.H., Qu, T., Raina, A., Alexander, P., and Tsao, E., J. Vaccines Vaccination, 2016, vol. 7, no. 1, p. 2.

    Article  Google Scholar 

  11. Ugarova, N.N., Lomakina, G.Yu., Modestova, Yu.A., Chernikov, S.V., Vinokurova, N.V., and Gorbachev, V.Y., J. Microbiol. Methods, 2016, vol. 130, no. 1, p. 48.

    Article  CAS  PubMed  Google Scholar 

  12. Cernuschi, T., Malvolti, S., Nickels, E., and Friede, M., Vaccine, 2018, vol. 36, no. 4, p. 498.

    Article  PubMed  PubMed Central  Google Scholar 

  13. WHO Expert Committee on Biological Standardization, report 62, Geneva, 2014, annex 3, p. 139.

  14. Ugarova, N.N., Koksharov, M.I., and Lomakina, G.Yu., RF Patent 2420594, Byull. Izobret., 2011, no. 16.

  15. Koksharov, M.I. and Ugarova, N.N., Protein Eng., Des. Sel., 2011, vol. 24, no. 11, p. 835.

    Article  CAS  Google Scholar 

  16. WHO/TB/Technical Guide/77/9: In vitro Assay of BCG Products, 1977, p. 1.

  17. Bland, J.M. and Altman, D.G., Lancet, 1986, vol. 327, p. 307.

    Article  Google Scholar 

  18. Giavarina, G., Biochem. Med., 2015, vol. 25, no. 2, p. 141.

    Article  Google Scholar 

Download references

Funding

The work was performed as part of state assignment no. AAAA-A16-116052010081-5 of Moscow State University and was supported by AO NPO Microgen (agreement nos. 702/16 and 400/17).

Author information

Authors and Affiliations

  1. Department of Chemistry, Moscow State University, Moscow, Russia

    N. N. Ugarova & G. Yu. Lomakina

  2. AO NPO Microgen, Moscow, Russia

    T. A. Perevyshina, E. V. Otrashevskaya & S. V. Chernikov

  3. Bauman Moscow State Technical University, Moscow, Russia

    G. Yu. Lomakina

Authors
  1. N. N. Ugarova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Yu. Lomakina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. A. Perevyshina
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. V. Otrashevskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. V. Chernikov
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. N. Ugarova.

Ethics declarations

The authors declare that they have no conflict of interest.

Additional information

Translated by A. Muravev

Abbreviations: ATP, adenosine-5'-triphosphate; CFUs, colony-forming units.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ugarova, N.N., Lomakina, G.Y., Perevyshina, T.A. et al. Controlling BCG Vaccine’s Cell Viability in the Process of Its Production by an Bioluminescent ATP Assay. Moscow Univ. Chem. Bull. 74, 191–197 (2019). https://doi.org/10.3103/S0027131419040084

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.3103/S0027131419040084

Keywords:

Search

Navigation